{
  "meta": {
    "data_length": 2,
    "message": "Statements retrieved successfully",
    "request_url": "http://api.moalmanac.org/statements?proposition_id=485&agent_id=fda&agent_id=ema",
    "status": "success",
    "status_code": 200,
    "timestamp_elapsed": 0.025476,
    "timestamp_received": "2026-06-10T00:48:24.129150+00:00Z",
    "timestamp_returned": "2026-06-10T00:48:24.154626+00:00Z",
    "trace_id": "c0f0a506-1163-4254-86ed-01da8cc5b083"
  },
  "service": {
    "github": "https://github.com/vanallenlab/moalmanac-db",
    "name": "Molecular Oncology Almanac",
    "license": "GPL-2.0",
    "release": "draft",
    "url": "https://dev.moalmanac.org",
    "last_updated": "2026-05-07"
  },
  "data": [
    {
      "id": 1136,
      "type": "Statement",
      "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
      "contributions": [
        {
          "id": 37,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "On 2025-09-26 the EMA granted initial market authorization to Voranigo (vorasidenib) for the treatment of patients with astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation.",
          "date": "2025-10-02"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:ema.voranigo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Voranigo (vorasidenib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Les Laboratoires Servier. Voranigo (vorasidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/voranigo-epar-product-information_en.pdf. Revised September 2025. Accessed October 2, 2025.",
          "urls": [
            "https://www.ema.europa.eu/en/medicines/human/EPAR/voranigo",
            "https://www.ema.europa.eu/en/documents/product-information/voranigo-epar-product-information_en.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-05",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.ema.europa.eu/en/medicines",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Les Laboratoires Servier",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Voranigo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "vorasidenib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2025-09-26",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2025-09-26",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:ema.voranigo:0",
        "indication": "Voranigo as monotherapy is indicated for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation in adult and adolescent patients aged 12 years and older and weighing at least 40 kg who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
        "initial_approval_date": "2025-09-17",
        "initial_approval_url": "https://www.ema.europa.eu/en/documents/assessment-report/voranigo-epar-public-assessment-report_en.pdf",
        "description": "The European Medicines Agency (EMA) has authorized vorasidenib as a monotherapy for the treatment of adult and adolescent patients aged 12 years and older with predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an IDH1 R132 or IDH2 R172 mutation. Eligible patients must be weighing at least 40 kg and who only had surgical intervention and are not in immediate need of radiotherapy or chemotherapy.",
        "raw_biomarkers": "IDH1 R132 or IDH2 R172",
        "raw_cancer_type": "astrocytoma or oligodendroglioma",
        "raw_therapeutics": "Voranigo (vorasidenib)",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": "2025-09-26",
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:ema.voranigo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Voranigo (vorasidenib) [product information]. EMA.",
          "title": null,
          "aliases": [],
          "description": "Les Laboratoires Servier. Voranigo (vorasidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/voranigo-epar-product-information_en.pdf. Revised September 2025. Accessed October 2, 2025.",
          "urls": [
            "https://www.ema.europa.eu/en/medicines/human/EPAR/voranigo",
            "https://www.ema.europa.eu/en/documents/product-information/voranigo-epar-product-information_en.pdf"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "ema",
                "type": "Agent",
                "agentType": "organization",
                "name": "European Medicines Agency",
                "description": "Regulatory agency that approves medicines for use in the European Union.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-05",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.ema.europa.eu/en/medicines",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Les Laboratoires Servier",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Voranigo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "vorasidenib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2025-09-26",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": null,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2025-09-26",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 485,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 112,
            "name": "IDH2 p.R172M",
            "genes": [
              {
                "id": 29,
                "name": "IDH2",
                "primaryCoding": {
                  "id": "hgnc:5383",
                  "code": "HGNC:5383",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383"
                  ]
                },
                "mappings": [
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_002168.4",
                      "code": "NM_002168.4",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000182054",
                      "code": "ENSG00000182054",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000182054"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:3418",
                      "code": "3418",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/3418"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "15q26.1"
                  },
                  {
                    "name": "location_sortable",
                    "value": "15q26.1"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Somatic Variant"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "chromosome",
                "value": "15"
              },
              {
                "name": "start_position",
                "value": 90631838
              },
              {
                "name": "end_position",
                "value": 90631838
              },
              {
                "name": "reference_allele",
                "value": "C"
              },
              {
                "name": "alternate_allele",
                "value": "A"
              },
              {
                "name": "cdna_change",
                "value": "c.515G>T"
              },
              {
                "name": "protein_change",
                "value": "p.R172M"
              },
              {
                "name": "variant_annotation",
                "value": "Missense"
              },
              {
                "name": "exon",
                "value": "4"
              },
              {
                "name": "rsid",
                "value": "rs121913503"
              },
              {
                "name": "hgvsg",
                "value": "15:g.90631838C>A"
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 6,
          "conceptType": "Disease",
          "name": "Astrocytoma",
          "primaryCoding": {
            "id": "oncotree:ASTR",
            "code": "ASTR",
            "name": "Astrocytoma",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 142,
          "conceptType": "Drug",
          "name": "Vorasidenib",
          "primaryCoding": {
            "id": "ncit:C152914",
            "code": "C152914",
            "name": "Vorasidenib",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "25.01d",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914"
            ]
          },
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "rxcui:2690647",
                "code": "2690647",
                "name": "vorasidenib",
                "system": "RxNorm",
                "systemVersion": "02-Mar-2026",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2690647"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:1735000",
                "code": "1735000",
                "name": "vorasidenib",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1735000"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "IDH1/2 inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ]
        }
      }
    },
    {
      "id": 565,
      "type": "Statement",
      "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
      "contributions": [
        {
          "id": 0,
          "type": "Contribution",
          "agent": {
            "id": "vanallenlab",
            "type": "Agent",
            "agentType": "contributor",
            "name": "Van Allen lab",
            "description": "Van Allen lab, Dana-Farber Cancer Institute",
            "last_updated": null,
            "url": null
          },
          "description": "Initial access of FDA approvals",
          "date": "2024-10-30"
        }
      ],
      "reportedIn": [
        {
          "id": "doc:fda.voranigo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Voranigo (vorasidenib) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Servier Pharmaceuticals LLC.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Voranigo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "vorasidenib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2024-08-06",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 218784,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-08-06",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      ],
      "direction": "supports",
      "indication": {
        "id": "ind:fda.voranigo:0",
        "indication": "VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
        "initial_approval_date": "2024-08-06",
        "initial_approval_url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf",
        "description": "The U.S. Food and Drug Administration (FDA) has granted approval to vorasidenib for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery including biopsy, sub-total resection, or gross total resection.",
        "raw_biomarkers": "IDH1 or IDH2 mutations",
        "raw_cancer_type": "astrocytoma or oligodendroglioma",
        "raw_therapeutics": "vorasidenib",
        "icd10": null,
        "regimen_code": null,
        "reimbursement_category": null,
        "reimbursement_date": null,
        "reimbursement_details": null,
        "date_regular_approval": null,
        "date_accelerated_approval": null,
        "document": {
          "id": "doc:fda.voranigo",
          "type": "Document",
          "documentType": "Regulatory approval",
          "name": "Voranigo (vorasidenib) [package insert]. FDA.",
          "title": null,
          "aliases": [],
          "description": "Servier Pharmaceuticals LLC. Voranigo (vorasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf. Revised August 2024. Accessed October 30, 2024.",
          "urls": [
            "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218784s000lbl.pdf",
            "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218784"
          ],
          "doi": null,
          "pmid": null,
          "extensions": [
            {
              "name": "agent",
              "value": {
                "id": "fda",
                "type": "Agent",
                "agentType": "organization",
                "name": "Food and Drug Administration",
                "description": "Regulatory agency that approves drugs for use in the United States.",
                "extensions": [
                  {
                    "name": "last_updated",
                    "value": "2026-05-07",
                    "description": ""
                  },
                  {
                    "name": "url",
                    "value": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm",
                    "description": ""
                  }
                ]
              },
              "description": "The organization that published this document."
            },
            {
              "name": "company",
              "value": "Servier Pharmaceuticals LLC.",
              "description": "The company that manufactures the cancer drug. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_brand",
              "value": "Voranigo",
              "description": "The brand name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "drug_name_generic",
              "value": "vorasidenib",
              "description": "The generic name of the cancer drug, per this document. Only applicable to market authorization documents."
            },
            {
              "name": "first_publication_date",
              "value": "2024-08-06",
              "description": "The publication date for the initial version of this document."
            },
            {
              "name": "identification_number",
              "value": 218784,
              "description": "Identification number used by the publishing organization."
            },
            {
              "name": "publication_date",
              "value": "2024-08-06",
              "description": "The publication date for the document."
            },
            {
              "name": "status",
              "value": "Active",
              "description": "Whether this document is Active or Deprecated within moalmanac-db."
            }
          ]
        }
      },
      "proposition": {
        "id": 485,
        "type": "VariantTherapeuticResponseProposition",
        "predicate": "predictSensitivityTo",
        "biomarkers": [
          {
            "id": 112,
            "name": "IDH2 p.R172M",
            "genes": [
              {
                "id": 29,
                "name": "IDH2",
                "primaryCoding": {
                  "id": "hgnc:5383",
                  "code": "HGNC:5383",
                  "name": null,
                  "system": "https://genenames.org",
                  "systemVersion": null,
                  "iris": [
                    "https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5383"
                  ]
                },
                "mappings": [
                  {
                    "relation": "relatedMatch",
                    "coding": {
                      "id": "refseq:NM_002168.4",
                      "code": "NM_002168.4",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/nuccore",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/nuccore/NM_002168.4"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ensembl:ensg00000182054",
                      "code": "ENSG00000182054",
                      "name": null,
                      "system": "https://www.ensembl.org",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ensembl.org/id/ENSG00000182054"
                      ]
                    }
                  },
                  {
                    "relation": "exactMatch",
                    "coding": {
                      "id": "ncbi:3418",
                      "code": "3418",
                      "name": null,
                      "system": "https://www.ncbi.nlm.nih.gov/gene",
                      "systemVersion": null,
                      "iris": [
                        "https://www.ncbi.nlm.nih.gov/gene/3418"
                      ]
                    }
                  }
                ],
                "extensions": [
                  {
                    "name": "location",
                    "value": "15q26.1"
                  },
                  {
                    "name": "location_sortable",
                    "value": "15q26.1"
                  }
                ]
              }
            ],
            "type": "CategoricalVariant",
            "extensions": [
              {
                "name": "biomarker_type",
                "value": "Somatic Variant"
              },
              {
                "name": "present",
                "value": true
              },
              {
                "name": "chromosome",
                "value": "15"
              },
              {
                "name": "start_position",
                "value": 90631838
              },
              {
                "name": "end_position",
                "value": 90631838
              },
              {
                "name": "reference_allele",
                "value": "C"
              },
              {
                "name": "alternate_allele",
                "value": "A"
              },
              {
                "name": "cdna_change",
                "value": "c.515G>T"
              },
              {
                "name": "protein_change",
                "value": "p.R172M"
              },
              {
                "name": "variant_annotation",
                "value": "Missense"
              },
              {
                "name": "exon",
                "value": "4"
              },
              {
                "name": "rsid",
                "value": "rs121913503"
              },
              {
                "name": "hgvsg",
                "value": "15:g.90631838C>A"
              }
            ]
          }
        ],
        "subjectVariant": {},
        "conditionQualifier": {
          "id": 6,
          "conceptType": "Disease",
          "name": "Astrocytoma",
          "primaryCoding": {
            "id": "oncotree:ASTR",
            "code": "ASTR",
            "name": "Astrocytoma",
            "system": "https://oncotree.mskcc.org",
            "systemVersion": "oncotree_2021_11_02",
            "iris": [
              "https://oncotree.mskcc.org/?version=oncotree_2021_11_02&field=CODE&search=ASTR"
            ]
          },
          "mappings": []
        },
        "objectTherapeutic": {
          "id": 142,
          "conceptType": "Drug",
          "name": "Vorasidenib",
          "primaryCoding": {
            "id": "ncit:C152914",
            "code": "C152914",
            "name": "Vorasidenib",
            "system": "https://evsexplore.semantics.cancer.gov",
            "systemVersion": "25.01d",
            "iris": [
              "https://evsexplore.semantics.cancer.gov/evsexplore/concept/ncit/C152914"
            ]
          },
          "mappings": [
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "rxcui:2690647",
                "code": "2690647",
                "name": "vorasidenib",
                "system": "RxNorm",
                "systemVersion": "02-Mar-2026",
                "iris": [
                  "https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=2690647"
                ]
              }
            },
            {
              "relation": "relatedMatch",
              "coding": {
                "id": "omop:1735000",
                "code": "1735000",
                "name": "vorasidenib",
                "system": "OMOP",
                "systemVersion": "v20260227",
                "iris": [
                  "https://athena.ohdsi.org/search-terms/terms/1735000"
                ]
              }
            }
          ],
          "extensions": [
            {
              "name": "therapy_strategy",
              "value": [
                "IDH1/2 inhibition"
              ],
              "description": "Associated therapeutic strategy or mechanism of action of the therapy."
            },
            {
              "name": "therapy_type",
              "value": "Targeted therapy",
              "description": "Type of cancer treatment from cancer.gov: https://www.cancer.gov/about-cancer/treatment/types"
            }
          ]
        }
      }
    }
  ]
}